JP5792726B2 - 過分極核を含む材料を作製する方法 - Google Patents
過分極核を含む材料を作製する方法 Download PDFInfo
- Publication number
- JP5792726B2 JP5792726B2 JP2012527097A JP2012527097A JP5792726B2 JP 5792726 B2 JP5792726 B2 JP 5792726B2 JP 2012527097 A JP2012527097 A JP 2012527097A JP 2012527097 A JP2012527097 A JP 2012527097A JP 5792726 B2 JP5792726 B2 JP 5792726B2
- Authority
- JP
- Japan
- Prior art keywords
- temperature
- polarization
- hyperpolarized
- magnetic field
- nuclei
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000463 material Substances 0.000 title claims description 481
- 238000004519 manufacturing process Methods 0.000 title claims description 18
- 230000010287 polarization Effects 0.000 claims description 144
- 230000005291 magnetic effect Effects 0.000 claims description 130
- 238000000034 method Methods 0.000 claims description 112
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 58
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 48
- 238000012546 transfer Methods 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 42
- 230000001965 increasing effect Effects 0.000 claims description 32
- 238000002844 melting Methods 0.000 claims description 32
- 230000008018 melting Effects 0.000 claims description 32
- 230000002102 hyperpolarization Effects 0.000 claims description 25
- 235000011054 acetic acid Nutrition 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 13
- 230000002238 attenuated effect Effects 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 229940107700 pyruvic acid Drugs 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 235000019253 formic acid Nutrition 0.000 claims description 4
- 239000003574 free electron Substances 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 230000005298 paramagnetic effect Effects 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000000243 solution Substances 0.000 description 44
- 239000008188 pellet Substances 0.000 description 37
- 239000007788 liquid Substances 0.000 description 36
- 239000007787 solid Substances 0.000 description 35
- 239000003795 chemical substances by application Substances 0.000 description 30
- 239000007789 gas Substances 0.000 description 30
- 238000002156 mixing Methods 0.000 description 26
- 238000005481 NMR spectroscopy Methods 0.000 description 25
- 238000001727 in vivo Methods 0.000 description 21
- 239000002243 precursor Substances 0.000 description 21
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 19
- 229960000583 acetic acid Drugs 0.000 description 19
- 239000001632 sodium acetate Substances 0.000 description 19
- 235000017281 sodium acetate Nutrition 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- OHSJPLSEQNCRLW-UHFFFAOYSA-N triphenylmethyl radical Chemical compound C1=CC=CC=C1[C](C=1C=CC=CC=1)C1=CC=CC=C1 OHSJPLSEQNCRLW-UHFFFAOYSA-N 0.000 description 15
- 230000008569 process Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 230000005641 tunneling Effects 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 239000001307 helium Substances 0.000 description 7
- 229910052734 helium Inorganic materials 0.000 description 7
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- 239000000084 colloidal system Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000008393 encapsulating agent Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229940054269 sodium pyruvate Drugs 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229910001868 water Inorganic materials 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- UQVKZNNCIHJZLS-UHFFFAOYSA-N PhIP Chemical compound C1=C2N(C)C(N)=NC2=NC=C1C1=CC=CC=C1 UQVKZNNCIHJZLS-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000011247 coating layer Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000028161 membrane depolarization Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000000859 sublimation Methods 0.000 description 3
- 230000008022 sublimation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 3
- QWGRWMMWNDWRQN-NCKGIQLSSA-N 1,1,3,3-tetradeuterio-2-(trideuteriomethyl)propane-1,3-diol Chemical compound [2H]C([2H])([2H])C(C([2H])([2H])O)C([2H])([2H])O QWGRWMMWNDWRQN-NCKGIQLSSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000000498 ball milling Methods 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000002999 depolarising effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 229940013688 formic acid Drugs 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000005283 ground state Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960000448 lactic acid Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- -1 methyl carbon Chemical group 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002907 paramagnetic material Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical group [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229910052724 xenon Inorganic materials 0.000 description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000446304 Vela Species 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- QTBSBXVTEAMEQO-GUEYOVJQSA-N acetic acid-d4 Chemical compound [2H]OC(=O)C([2H])([2H])[2H] QTBSBXVTEAMEQO-GUEYOVJQSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000004078 cryogenic material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229910000595 mu-metal Inorganic materials 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 150000002835 noble gases Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/28—Details of apparatus provided for in groups G01R33/44 - G01R33/64
- G01R33/282—Means specially adapted for hyperpolarisation or for hyperpolarised contrast agents, e.g. for the generation of hyperpolarised gases using optical pumping cells, for storing hyperpolarised contrast agents or for the determination of the polarisation of a hyperpolarised contrast agent
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23864709P | 2009-08-31 | 2009-08-31 | |
| US61/238,647 | 2009-08-31 | ||
| PCT/US2010/047310 WO2011026103A2 (en) | 2009-08-31 | 2010-08-31 | Systems and methods for producing hyperpolarized materials and mixtures thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013503021A JP2013503021A (ja) | 2013-01-31 |
| JP2013503021A5 JP2013503021A5 (enExample) | 2013-10-17 |
| JP5792726B2 true JP5792726B2 (ja) | 2015-10-14 |
Family
ID=43628703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012527097A Expired - Fee Related JP5792726B2 (ja) | 2009-08-31 | 2010-08-31 | 過分極核を含む材料を作製する方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2473198A4 (enExample) |
| JP (1) | JP5792726B2 (enExample) |
| KR (1) | KR20120101339A (enExample) |
| CN (1) | CN102753201A (enExample) |
| AU (1) | AU2010286413B2 (enExample) |
| CA (1) | CA2772190A1 (enExample) |
| IN (1) | IN2012DN02418A (enExample) |
| SG (1) | SG178927A1 (enExample) |
| WO (1) | WO2011026103A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007254464B2 (en) | 2006-02-21 | 2013-02-21 | Avrum Belzer | Hyperpolarization methods, systems and compositions |
| US8703102B2 (en) | 2008-04-04 | 2014-04-22 | Millikelvin Technologies Llc | Systems and methods for producing hyperpolarized materials and mixtures thereof |
| GB2498181A (en) | 2011-12-29 | 2013-07-10 | Bruker Biospin Gmbh | Device and method for rapid dynamic nuclear polarisation |
| US9329246B2 (en) | 2012-10-03 | 2016-05-03 | Bruker Biospin Ag | Method for hyperpolarization transfer in the liquid state |
| US9404984B2 (en) | 2012-11-06 | 2016-08-02 | Bruker Uk Limited | Method of hyperpolarization applying brute force using particulate acceleration agents |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545396A (en) * | 1994-04-08 | 1996-08-13 | The Research Foundation Of State University Of New York | Magnetic resonance imaging using hyperpolarized noble gases |
| US5617859A (en) | 1995-10-02 | 1997-04-08 | General Electric Company | Apparatus and methods for magnetic resonance (MR) imaging of cavities using fluids polarized at low temperatures |
| RU2186405C2 (ru) | 1996-03-29 | 2002-07-27 | Лоренс Беркли Нэшнл Лэборэтори | Усиление ядерного магнитного резонанса (ямр) и магниторезонансной визуализации (мрв) в присутствии гиперполяризованных благородных газов |
| CN1224502A (zh) * | 1996-03-29 | 1999-07-28 | 劳伦斯·伯克利国家实验室 | 利用超极化惰性气体对于核磁共振和磁共振成象质量的提高 |
| US5809801A (en) * | 1996-03-29 | 1998-09-22 | The Trustees Of Princeton University | Cryogenic accumulator for spin-polarized xenon-129 |
| GB9614139D0 (en) | 1996-07-05 | 1996-09-04 | Nycomed Imaging As | Method |
| DE69820415T2 (de) * | 1997-01-08 | 2004-09-16 | Amersham Health As | Verfahren zur bilderzeugung mit magnetischer resonanz |
| AU8119298A (en) * | 1997-06-19 | 1999-01-04 | Nycomed Imaging As | Overhauser magnetic resonance imaging (ormi) method comprising ex vivo polarization of a magnetic resonance (mr) imaging agent |
| WO1999024080A1 (en) | 1997-11-12 | 1999-05-20 | Nycomed Imaging As | Para-hydrogen labelled agents and their use in magnetic resonance imaging |
| US6278893B1 (en) * | 1998-01-05 | 2001-08-21 | Nycomed Imaging As | Method of magnetic resonance imaging of a sample with ex vivo polarization of an MR imaging agent |
| GB0001727D0 (en) | 2000-01-25 | 2000-03-15 | Oxford Instr Uk Ltd | Hyperpolarization of a noble gas |
| AU1403902A (en) | 2000-11-03 | 2002-05-15 | Amersham Health As | Methods and devices for polarised nmr samples |
| US7372274B2 (en) * | 2000-11-03 | 2008-05-13 | Ge Healthcare As | Methods and devices configured for dissolving hyperpolarised solid material with a solvent within a cryostat for NMR analyses |
| NO20025738D0 (no) * | 2002-11-29 | 2002-11-29 | Amersham Health As | Metode |
| DE102004002639A1 (de) * | 2004-01-19 | 2005-09-15 | Forschungszentrum Jülich GmbH | Verfahren zur Anreicherung von hyperpolarisierten Atomkernen und Vorrichtung zur Durchführung des Verfahrens |
| GB0501346D0 (en) * | 2005-01-21 | 2005-03-02 | Oxford Instr Molecular Biotool | Method of carrying out dynamic nuclear polarization |
| FR2881226B1 (fr) * | 2005-01-27 | 2007-04-27 | Commissariat Energie Atomique | Accroissement de la polarisation des spins nucleaires d'une molecule via un transfert de polarisation de type hartmann-hahn utilisant le champ dipolaire moyen cree par une source |
| GB0514303D0 (en) * | 2005-07-12 | 2005-08-17 | Oxford Instr Molecular Biotool | Magnet assembly |
| AU2007254464B2 (en) * | 2006-02-21 | 2013-02-21 | Avrum Belzer | Hyperpolarization methods, systems and compositions |
| NL2000122C2 (nl) * | 2006-07-03 | 2008-01-07 | Vialle Alternative Fuel System | Bufferhouder. |
| US7631507B2 (en) * | 2006-11-02 | 2009-12-15 | General Electric Company | Methods and devices for polarized samples for use in MRI |
| US20080242974A1 (en) * | 2007-04-02 | 2008-10-02 | Urbahn John A | Method and apparatus to hyperpolarize materials for enhanced mr techniques |
| US7519492B2 (en) * | 2007-05-02 | 2009-04-14 | General Electric Company | Apparatus and method for fully automated closed system quality control of a substance |
-
2010
- 2010-08-31 EP EP10812752.3A patent/EP2473198A4/en not_active Withdrawn
- 2010-08-31 SG SG2012014379A patent/SG178927A1/en unknown
- 2010-08-31 IN IN2418DEN2012 patent/IN2012DN02418A/en unknown
- 2010-08-31 JP JP2012527097A patent/JP5792726B2/ja not_active Expired - Fee Related
- 2010-08-31 CA CA2772190A patent/CA2772190A1/en not_active Abandoned
- 2010-08-31 AU AU2010286413A patent/AU2010286413B2/en not_active Ceased
- 2010-08-31 KR KR1020127008209A patent/KR20120101339A/ko not_active Ceased
- 2010-08-31 WO PCT/US2010/047310 patent/WO2011026103A2/en not_active Ceased
- 2010-08-31 CN CN2010800471391A patent/CN102753201A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2473198A4 (en) | 2015-06-24 |
| CA2772190A1 (en) | 2011-03-03 |
| WO2011026103A2 (en) | 2011-03-03 |
| CN102753201A (zh) | 2012-10-24 |
| KR20120101339A (ko) | 2012-09-13 |
| JP2013503021A (ja) | 2013-01-31 |
| EP2473198A2 (en) | 2012-07-11 |
| SG178927A1 (en) | 2012-04-27 |
| WO2011026103A3 (en) | 2011-07-21 |
| AU2010286413B2 (en) | 2014-11-20 |
| AU2010286413A1 (en) | 2012-04-05 |
| IN2012DN02418A (enExample) | 2015-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8703102B2 (en) | Systems and methods for producing hyperpolarized materials and mixtures thereof | |
| JP4764548B2 (ja) | 磁気共鳴調査方法 | |
| CA2643306C (en) | Hyperpolarization methods, systems and compositions | |
| JP5792726B2 (ja) | 過分極核を含む材料を作製する方法 | |
| US20140223923A1 (en) | Systems and methods for producing hyperpolarized materials and mixtures thereof | |
| US20110050228A1 (en) | agent for transporting nuclear spin order and for magnetic resonance imaging | |
| EP2917749B1 (en) | Method of hyperpolarization applying brute force using particulate acceleration agents | |
| JP4420224B2 (ja) | 過分極１２９Ｘｅの製造法 | |
| CA2720333C (en) | Manufacture, transport and delivery of material containing highly polarized nuclei | |
| O'Neill | Brute force polarisation of xenon-129 | |
| Månsson | Hyperpolarized Nuclei for NMR Imaging and Spectroscopy–Methodology and model studies of lung and vascular function | |
| AU2016204108A1 (en) | Hyperpolarization Methods, Systems and Compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130822 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130822 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140430 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140521 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140820 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140827 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141121 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150331 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150626 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150728 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150806 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5792726 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |